A study to determine the natural history and outcome measures for clinical trials in Becker MD and sporadic (nongenetic) inclusion-body myositis is open in Ohio

posted on November 18, 2013 - 5:00am
A study to determine the best outcome measures — ways to evaluate the effects of a treatment — for use in clinical studies in Becker muscular dystrophy (BMD) and sporadic (nongenetic) inclusion-body myositis (sIBM) is underway at Nationwide Children's Hospital in Columbus, Ohio, under the supervision of neurologist Jerry Mendell working with physical therapists Linda Lowes and

In this second report on MDA's Clinical Conference, updates on experimental therapies in development for six neuromuscular diseases are described

posted on April 6, 2012 - 6:00am
The progress of several experimental therapies currently in development for neuromuscular diseases was discussed at MDA's 2012 Clinical Conference, held in Las Vegas March 4-7.

Quest takes a look at gene therapy, 'antisense' and other cutting-edge scientific approaches and how they're being applied to diseases in MDA's program

posted on July 1, 2011 - 4:15pm
QUEST Vol. 18, No. 3
Antisense oligonucleotides block flawed genetic instructions Antisense oligonucleotides — also called antisense, oligos, or simply AONs — are pieces of genetic code that keep other genetic code from being processed. Designed to pair up with a particular sequence of DNA or RNA, AONs can change, block or destroy targeted genetic instructions in a variety of ways.

New treatments bring relief in inflammatory muscle disease, but patience is required

posted on January 1, 2004 - 10:52am
Giovanna Albers, 38, has recovered from her polymyositis and no longer takes medication for it. Her weight is back to normal, and she "lives and breathes" in the water. Photo by Tim Parker